MAP2K7 and central nervous system cancer: Although mitogen-activated protein kinase (MEK) inhibitors are more commonly used in the adult population [12], there is growing use of it in pediatric gliomas [13], which accounts for nearly one third of pediatric central nervous system tumors [14].